1,2-Dimethoxybenzene

1,2-Dimethoxybenzene

SCHEMBL66189

COc1ccccc1OC.O=S(=O)(Cl)Cl

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.68
CA2 P00918 4/20 0.68
CA7 P43166 2/20 0.68
CA9 Q16790 2/20 0.68
CA12 O43570 1/20 0.68
CA4 P22748 1/20 0.68
CA14 Q9ULX7 1/20 0.68
ALDH1A1 P00352 3/20 0.52
MAPK1 P28482 2/20 0.52
HTT P42858 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
HTR6 P50406 1/20 0.52
NFE2L2 Q16236 2/20 0.49
TSHR P16473 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
TP53 P04637 1/20 0.48
ADRA2B P18089 1/20 0.48
PTGS1 P23219 1/20 0.48
POLB P06746 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
1,2-Dimethoxybenzene SCHEMBL10453010 0.90 CA1 (0.62) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL27865611 0.89 CA12 (0.54) CA1CA2CA7CA9CA12
SCHEMBL3904409 0.86 NFE2L2 (0.51) CA1CA2CA7CA9CA12
Guaiacol SCHEMBL27732358 0.84 CA1 (0.75) CA1CA2CA7CA9CA12
SCHEMBL1611608 0.84 CA1 (0.48) CA1CA2CA7CA9CA12
SCHEMBL2494769 0.83 SMN1; SMN2 (0.48) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL105872 0.83 CA1 (1.00) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL5308636 0.83 CA1 (1.00) CA1CA2CA7CA9CA12
1,2-Dimethoxybenzene SCHEMBL29351917 0.83 CA1 (1.00) CA1CA2CA7CA9CA12
SCHEMBL74380 0.81 HTR6 (0.60) CA1CA2CA7CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109516987-B Preparation method of avibactam intermediate 江西富祥药业股份有限公司 2020-07-24 CN claimed
US-20240413334-A1 BINDER AND LITHIUM-ION BATTERY INCLUDING SAME ZHUHAI COSMX BATTERY CO., LTD. (CN) 2024-12-12 US disclosed
CN-114591312-B Sulfone and sulfoxide compounds, preparation method and medical application thereof 中国药科大学 2023-07-28 CN disclosed
WO-2022018462-A1 CATECHOL BASED DERIVATIVES FOR USE IN THE PREVENTION OF DNA DAMAGE UNIVERSITY OF NEWCASTLE UPON TYNE (GB) 2022-01-27 WO disclosed
EP-3212613-B1 (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS COUNCIL SCIENT IND RES (IN) 2020-12-16 EP disclosed
CN-109761980-B 3-aminosulfonylamino-substituted rutaecarpine derivative and preparation method and application thereof 安徽医科大学 2020-11-24 CN disclosed
CN-110256305-A A kind of naphthalenesulfonamide compound, preparation method and application 中国药科大学 2019-09-20 CN disclosed
US-10246411-B2 (Z)-3,4,5-trimethoxystyrylbenzenesulfonamides as potential anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2019-04-02 US disclosed
US-20170327462-A1 (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-11-16 US disclosed
EP-3212613-A1 (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS Council of Scientific and Industrial Research (IN) 2017-09-06 EP disclosed
WO-1999026616-A1 BENZENESULFONAMIDE INHIBITORS OF PDE-IV AND THEIR THERAPEUTIC USE WARNER-LAMBERT COMPANY (US) 1999-06-03 WO disclosed
CN-1207095-A Protease inhibitors SMITHKLINE BEECHAM CORP (US) 1999-02-03 CN disclosed
CN-1176101-A N -(4 -aryl -thiazol -2 -yl) -sulphonamide derivatives and their use HOFFMANN LA ROCHE (CH) 1998-03-18 CN disclosed
US-5728712-A 3,4-disubstituted-phenylsulphonamides and their therapeutic use CHIROSCIENCE LIMITED (GB) 1998-03-17 US disclosed
WO-1998008815-A1 SUBSTITUTED CYCLIC AMINE METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1998-03-05 WO disclosed
WO-1996036611-A1 3,4-DISUBSTITUTED-PHENYLSULPHONAMIDES AND THEIR THERAPEUTIC USE CHIROSCIENCE LIMITED (GB) 1996-11-21 WO disclosed
EP-0412763-B1 Cephalosporins, processes for their preparation, pharmaceutical compositions containing them and intermediates therefor ZENECA LTD (GB) 1996-07-10 EP disclosed
US-5219848-A Bactericides ICI PHARMA (FR) 1993-06-15 US disclosed
EP-0412763-A2 Cephalosporins, processes for their preparation, pharmaceutical compositions containing them and intermediates therefor ZENECA LIMITED (GB) 1991-02-13 EP disclosed
US-4720580-A N-(aminoalkylene)benzenesulfonamides AMERICAN HOME PRODUCTS CORPORATION (US) 1988-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246411-B2 (Z)-3,4,5-trimethoxystyrylbenzenesulfonamides as potential anticancer agents BCL3, CASP3, HCCS CA1 1312/4885CA2 1347/4885CA7 163/4885
US-20170327462-A1 (Z)-3,4,5-TRIMETHOXYSTYRYLBENZENESULFONAMIDES AS POTENTIAL ANTICANCER AGENTS BCL3, CASP3, HCCS CA1 2478/4885CA2 2281/4885CA7 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.